Developmental Biology Program
The Danwei Huangfu Lab
Research
Featured News
Publications Highlights
Glucose transporters are key components of the human glucostat. Caspi I, Tremmel DM, Pulecio J, Yang D, Liu D, Yan J, Odorico JS, Huangfu D. Diabetes. 2024 May 22:db230508. doi: 10.2337/db23-0508. Online ahead of print. [PMID: 38775784] (first author(s) from the Huangfu lab are shown in bold)
Dynamic network-guided CRISPRi screen identifies CTCF-loop-constrained nonlinear enhancer gene regulatory activity during cell state transitions. Luo R, Yan J, Oh JW, Xi W, Shigaki D, Wong W, Cho HS, Murphy D, Cutler R, Rosen BP, Pulecio J, Yang D, Glenn RA, Chen T, Li QV, Vierbuchen T, Sidoli S, Apostolou E, Huangfu D#, Beer MA#. Nat Genet. 2023 Aug;55(8):1336-1346. doi: 10.1038/s41588-023-01450-7. Epub 2023 Jul 24. [PMID: 37488417] (#co-corresponding author)
CRISPR screening uncovers a central requirement for HHEX in pancreatic lineage commitment and plasticity restriction. Yang D, Cho H, Tayyebi Z, Shukla A, Luo R, Dixon G, Ursu V, Stransky S, Tremmel DM, Sackett SD, Koche R, Kaplan SJ, Li QV, Park J, Zhu Z, Rosen BP, Pulecio J, Shi ZD, Bram Y, Schwartz RE, Odorico JS, Sidoli S, Wright CV, Leslie CS#, Huangfu D#. Nat Cell Biol. 2022 Jul;24(7):1064-1076. doi: 10.1038/s41556-022-00946-4. Epub 2022 Jul 4. [PMID: 35787684]
QSER1 protects DNA methylation valleys from de novo methylation. Dixon G, Pan H, Yang D, Rosen BP, Jashari T, Verma N, Pulecio J, Caspi I, Lee K, Stransky S, Glezer A, Liu C, Rivas M, Kumar R, Lan Y, Torregroza I, He C, Sidoli S, Evans T, Elemento O#, Huangfu D#. Science. 2021 Apr 9;372(6538):eabd0875. doi: 10.1126/science.abd0875. [PMID: 33833093]
Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation. Li QV, Dixon G, Verma N, Rosen BP, Gordillo M, Luo R, Xu C, Wang Q, Soh CL, Yang D, Crespo M, Shukla A, Xiang Q, Dündar F, Zumbo P, Witkin M, Koche R, Betel D, Chen S, Massagué J, Garippa R, Evans T, Beer MA#, Huangfu D#. Nat Genet. 2019 Jun;51(6):999-1010. doi: 10.1038/s41588-019-0408-9. Epub 2019 May 20. [PMID: 31110351]
People
Danwei Huangfu, PhD
- The Huangfu laboratory uses human pluripotent stem cells (hPSCs) as a powerful genetic model to interrogate the transcriptional and epigenetic mechanisms underlying cell fate decisions in development and disease.
- PhD, Cornell University, Weill Graduate School of Medical Sciences
- BS, Fudan University
- huangfud@mskcc.org
- Email Address
- Download CV
- PDF File
Members
- PhD, International Centre for Genetic Engineering and Biotechnology [ICGEB]
- PhD, Columbia University
- PhD, CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences
- BS, Shanghai Jiaotong University
- Cancer Biology
- PhD, Institute of Life Sciences, Odisha (India)
- PhD, Icahn School of Medicine at Mount Sinai
- PhD, Helmholtz Zentrum München German Research Center for Environmental Health
- PhD, New York University School of Medicine
- BA, University of California, Berkeley
- MS, Imperial College London
- University of Arizona
- BS, Shanghai Jiaotong University
- BS, CUNY Hunter College
- PhD, Weill Cornell Graduate School of Medical Sciences
- Bachelor of Technology, National Institute of Technology Calicut
- MS, University of Minnesota Twin Cities
- PhD, Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India
- PhD, University of Illinois at Chicago
- BS, University of Chicago
Achievements
- Basil O’Connor Scholar, March of Dimes Birth Defects Foundation (2012-2014)
- Louis V. Gerstner, Jr. Young Investigators Award, Memorial Sloan Kettering Cancer Center (2011-2014)
- Award from Harvard Catalyst & InnoCentive for the Ideation Challenge on “What Do We Not Know to Cure Type 1 Diabetes” (2010)
- Helen Hay Whitney Postdoctoral Fellowship (2006-2009)
Lab News & Events
Accolades
Team Recognitions
-
Denis Torre - Damon Runyon Cancer Research Foundation Fellowship (2025)
-
Tamara Casteels - Emerald Foundation Postdoctoral Fellowship (2025)
-
Pallavi Mohapatra - Kaufman Family Postdoctoral Fellowship in Pediatric Cancer (2025)
-
Renhe Luo - GSK Chairman’s Prize (2024)
-
Julian Pulecio - 2023 cohort of MERIT Emerging Leaders
-
Dingyu Liu - Bruce Charles Forbes Fellowship (2023)
-
Tamara Casteels - NYSTEM Training Award at the CSCB (2022)
-
Tamara Casteels - Award of Excellence for her PhD thesis with Stefan Kubicek in CeMM (2022)
-
Nan Zhang - CDMRP PRMRP Discovery Award (2022)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Graduate Student, Postdoctoral Fellow, Research Technician and Project Manager
Get in Touch
-
Lab Head Email
-
Lab Phone
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Danwei Huangfu discloses the following relationships and financial interests:
-
Breakthrough T1D
Professional Services and Activities
-
Stem Cell Reports
Professional Services and Activities (Uncompensated)
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.